Cytokinetics, Inc. (NASDAQ:CYTK) might end its experiments in Lou Gehrig disease after this negative outcome in second stage testing. Cytokinetics in conjunction with Amgen Inc. is in the testing stage for a cardiac muscle program named Omecativ mecarbil. In 2013, the drug did not meet its goals in a clinical trial. Cytokinetics, Inc. (NASDAQ:CYTK) shares after opening at $4.58 moved to $4.59 on last trade day and at the end of the day closed at $4.46. Company price to sales ratio in past twelve months was calculated as 5.26 and price to cash ratio as 2.07. Cytokinetics, Inc. (NASDAQ:CYTK) showed a negative weekly performance of -58.70%.
OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) and Teva Pharmaceutical (TEVA: Quote) announced Monday morning that the Phase III SYNERGY trial comparing the combination of custirsen and standard first-line docetaxel/prednisone therapy to docetaxel/prednisone alone in men with metastatic castrate-resistant prostate cancer did not meet the primary endpoint. OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) shares fell -60.31% in last trading session and ended the day on $3.85. OGXI return on equity ratio is recorded as -65.90% and its return on assets is -48.70%. OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) yearly performance is -62.25%.
Zacks upgraded shares of Agenus (NASDAQ:AGEN) from a neutral rating to an outperform rating in a research report sent to investors on Monday morning. The firm currently has $3.00 price target on the stock. Agenus Inc (NASDAQ:AGEN) shares moved up 19.53% in last trading session and was closed at $3.06, while trading in range of $2.72-$3.12. Agenus Inc (NASDAQ:AGEN) year to date performance is 15.91%.
On April 22, 2014 Oragenics, Inc. (NYSEMKT:OGEN), a leader in the development of novel, effective antibiotics and oral care probiotics, announced that Mr. Al Fosmoe has joined Oragenics as Senior Vice President Operations/Product Development. The appointment is directly related to the progress Oragenics has made in the development of a new pipeline of novel antibiotics from its lantibiotic platform, and marks the expansion of the team dedicated to accelerating the progress of the lantibiotic pipeline.Oragenics Inc (NYSEMKT:OGEN) weekly performance is -13.07%. On last trading day company shares ended up $1.93. Oragenics Inc (NYSEMKT:OGEN) distance from 50-day simple moving average is -35.47%. Analysts mean target price for the company is $7.00.